Consent given pursuant to Sections 14 & 14A to the supply of the therapeutic goods specified by Symbion Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring they are safe and of high quality. This Act was introduced to address the need for a comprehensive legal framework governing the importation, supply, and advertising of therapeutic goods, including medicines, medical devices, and blood products. The Act is administered by the Therapeutic Goods Administration, an agency of the Department of Health within the Australian Government. The policy objective behind the Act is to protect and promote public health by controlling the quality, efficacy, and safety of therapeutic goods available in the market. The legislative framework allows for the regulation of therapeutic goods throughout their lifecycle, from manufacturing and importation to advertising and post-market surveillance. The consent granted under sections 14 and 14A of the Act, as illustrated in the example provided, allows for temporary exceptions to certain regulatory requirements, ensuring that the supply of therapeutic goods can continue while addressing specific compliance issues.

Scope and Application

The Therapeutic Goods Act 1989, under sections 14 and 14A, applies to the regulation and administration of therapeutic goods in Australia, encompassing products such as medicines, medical devices, and blood and blood components. The Act governs entities and persons involved in the supply and importation of these goods, ensuring that they meet specific safety, quality, and efficacy standards. The scope of the Act extends to all therapeutic goods in the Commonwealth, with its provisions applicable nationwide, including across states, territories, and all jurisdictions within Australia. However, the Act does not apply to certain goods such as cosmetics, dietary supplements, or goods used solely for personal purposes excluding any commercial use. The application of the Act may also be extended or restricted through subordinate instruments, such as regulations or orders, which provide additional detail or specific requirements. For example, the Therapeutic Goods Order No. 69 sets out the general requirements for labels for medicines, and deviations from these, as seen in the consent granted to Symbion Pty Ltd for specific batches of ibuprofen products, must be approved under the Act.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) provide a framework for the supply of therapeutic goods that do not fully comply with certain regulatory standards, subject to the consent of a delegate of the Secretary of the Department of Health. In this instance, Symbion Pty Ltd applied for and received consent to supply specific batches of ibuprofen products that did not meet the label requirements outlined in Therapeutic Goods Order No. 69. Specifically, these products failed to include all of the advisory statements required by the Medicines Advisory Statements Specifications 2014. The consent granted under these sections is narrowly tailored to address the non-compliance and applies only to the specified batches and time frame. The obligations imposed by this Act on the parties involved are primarily focused on ensuring that any non-compliant therapeutic goods are supplied under controlled conditions that mitigate potential risks to consumers. Symbion Pty Ltd must adhere to the specific conditions of the consent, which include using the previously approved labels for the affected batches. These labels must be those that were submitted with the application and approved by the relevant authorities. Additionally, the company must ensure that these products are only supplied within the specified period, from 13 January 2016 to 12 June 2016, and only for the batches listed in the table. These conditions are designed to limit exposure to the non-compliant products and allow for corrective action to be taken without unduly impacting consumers. Failure to comply with the terms of the consent or the conditions set out in the Act can lead to various consequences. Under the Therapeutic Goods Act 1989, breaches may result in both civil and criminal penalties. For example, supplying therapeutic goods without the required consent or outside the specified conditions can be considered an offence. The penalties for such offences can be significant, with maximum penalties including fines of up to $222,000 for individuals and $1,110,000 for corporations, depending on the severity and intent of the breach. Additionally, ongoing non-compliance or repeated offences can lead to further legal action, including potential imprisonment for individuals involved in the management of the non-compliant supply.